LXRX
Lexicon Pharmaceuticals Inc
1.70$
-4.4%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| -42.6% | -18.1% | 22.4% | 249.4% | 219.5% | 157.4% | 132.3% | 160.5% | 231.1% | 374.1% | 883.1% | 1,866.8% | 5,597.1% | 7,582.6% | 4,036.1% | 390.6% | 73.2% | 196.8% | 2.1% | 3.9% | 1.0% | 8.0% | 18,471.8% | 37,781.3% | 4,898.0% | 2.0% | 0.6% | |
| 142.6% | 118.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -7,482.6% | -3,936.1% | -290.6% | 26.8% | -96.8% | 97.9% | 96.1% | 99.0% | 92.0% | -18,371.8% | -37,681.3% | -4,798.0% | 98.0% | 99.4% | |
| 310.6% | 218.9% | 17.5% | 212.7% | 191.9% | 146.7% | 123.7% | 146.6% | 208.2% | 335.9% | 759.2% | 1,535.2% | 4,966.4% | 7,582.6% | 4,036.1% | 390.6% | 73.2% | 213.8% | 173.6% | 158.6% | 28.5% | 640.2% | 18,471.8% | 37,997.1% | 4,890.9% | 271.8% | 122.7% | |
| – | 126.5% | 6.8% | 66.0% | 54.2% | 30.1% | 24.0% | 29.3% | 41.4% | 62.7% | 181.5% | 459.8% | 938.3% | 1,565.0% | 770.5% | 84.9% | 18.3% | 51.7% | 73.3% | 100.9% | 17.6% | 0.2% | 10,853.0% | 34,592.1% | 8,115.0% | 460.4% | 74.9% | |
| 414.9% | 363.5% | 114.3% | 278.7% | 246.1% | 176.9% | 147.7% | 175.9% | 249.6% | 398.7% | 940.7% | 2,050.2% | 6,270.6% | 9,147.6% | 4,806.6% | 475.6% | 91.5% | 265.4% | 246.9% | 259.5% | 55.1% | 291.2% | 10,853.0% | 34,807.9% | 9,466.9% | 732.2% | 197.7% | |
| -272.3% | -245.4% | -14.3% | -178.7% | -146.1% | -76.9% | -47.7% | -75.9% | -149.6% | -298.7% | -840.7% | -1,950.2% | -6,170.6% | -9,955.5% | -4,607.2% | -439.2% | 1.1% | -164.6% | -151.3% | -163.4% | 43.9% | -199.2% | -29,224.8% | -72,489.2% | -14,265.0% | -634.2% | -98.2% | |
| 0.0% | 2.9% | 0.1% | 0.0% | 0.8% | 4.3% | 4.3% | 4.5% | 5.5% | 8.3% | 27.7% | 55.4% | 136.7% | 194.1% | 88.7% | 9.9% | 5.2% | 7.9% | 7.7% | 32.9% | 6.4% | 60.6% | 269.1% | 2,000.0% | 1,088.1% | 50.1% | 16.7% | |
| – | – | – | – | – | -74.7% | 51.8% | 74.8% | -142.1% | -299.8% | -873.1% | -2,074.2% | -6,285.3% | -10,120.4% | -4,686.1% | -439.2% | -3.6% | -169.7% | -156.9% | -190.7% | 38.5% | -244.1% | -29,449.0% | -73,341.0% | -14,710.9% | -644.8% | -101.1% | |
| -6.4% | -65.6% | -2.8% | -9.2% | 3.7% | -0.5% | 0.2% | -0.2% | -32.2% | -60.9% | -1.0% | -0.5% | -127.6% | -181.0% | -37.5% | -0.3% | 4.6% | 5.4% | -14.0% | 5.5% | -1.9% | 48.4% | 171.1% | 851.8% | 32.1% | -644.8% | – | |
| -266.0% | -179.8% | -11.5% | -169.5% | -149.9% | -76.4% | -48.0% | -74.6% | -117.3% | -237.8% | -773.6% | -2,073.7% | -6,285.3% | -10,120.4% | -4,686.1% | -438.8% | -3.6% | -169.7% | -142.9% | -190.7% | 40.4% | -244.1% | -29,449.0% | -73,341.0% | -14,710.9% | -644.8% | -101.1% | |
| -229.8% | -227.2% | -8.9% | -120.2% | -95.9% | -56.0% | -32.4% | -54.9% | -128.8% | -266.9% | -787.8% | -1,908.9% | -5,884.3% | -9,541.5% | -4,468.6% | -420.9% | 9.0% | -151.0% | -138.7% | -152.0% | 46.1% | -171.3% | -29,081.9% | -71,966.2% | -14,099.3% | -592.9% | -83.1% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.